Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors

Brief description of study

If you have been diagnosed with advanced or metastatic solid tumors, you may qualify for this Phase I study. The main goal of this study is to test the safety of the investigational drug, MK-7162 given in combination with pembrolizumab for patients with advanced solid tumors.

Clinical Study Identifier: s17-01300 Identifier: NCT03364049
Principal Investigator: Daniel C Cho
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.